BY BENJAMIN WERNER CHRISTENSEN, FINANS, TRANSLATED BY NIELSINE NIELSEN
The highly affluent Lundbeck Foundation turns up its level of ambition and gets ready to place some of the fund's fortune in worthy companies.
In the next couple of years, the foundation will acquire massive owner's shares in up to five more companies, so the portfolio will no longer "just" consist of a controlling owner's share in the pharmaceutical companies Lundbeck and ALK and the Danish safety and healthcare company Falck.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Nordic Medical Affairs Manager 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Chemist for Incoming Materials in QC Department 
Senior QA Specialist 
Senior Chemical Safety Advisor 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Clinical Project Manager 
Project Manager & Scrum Master 
Senior Project Manager (GMP - Life Science) 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Clinical Trial Manager for development of in vitro diagnostics 
IRT Manager, Clinical Drug Supply 
Director Global Engineering 
(Senior) Drug Substance Specialist 
Consultant Manager 
Client Talent Acquisition Specialist